The Latest Cardiac and Vascular News
Mentice and Siemens Healthineers China announce that Mentice VIST ® Virtual Patient simulators will be included with the sale of every Corindus CorPath GRX Robotic system (CorPath GRX) in China on an initial 3-year agreement, starting 2022. GOTHENBURG, Sweden, Dec. 27, 2021 /PRNewswire/ — Mentice, a world leader in simulation solutions for image-guided […]
To be Published in the International Journal of Cardiology SEATTLE, Dec. 27, 2021 (GLOBE NEWSWIRE) — Faraday Pharmaceuticals, Inc., a muscle health-focused biopharmaceutical company developing therapeutics to treat patients experiencing potentially life changing critical illness, announced today the publication of results from its Phase 2 trial of FDY-5301 for the […]
– ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters, respectively. Both declines are similar to healthy elderly adults and less than prior untreated ATTR-CM cohorts – The company observed […]
The objective of this study is to evaluate safety and effectiveness of the Lacrosse NSE ALPHA coronary dilatation catheter during PCI in subjects with stenotic coronary arteries. BEDFORD, Mass.–(BUSINESS WIRE)–Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first […]
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the completion of investigations on its prostheses. Following the occurrence of […]
– With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol) reduction(1) – Leqvio provides effective and sustained LDL-C reduction of up to 52% vs. placebo for certain people with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin […]
SAN FRANCISCO, CA, and TORONTO, ON, Dec. 22, 2021 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that it will develop R-107 for the treatment of persistent pulmonary hypertension of the newborn (“PPHN”). PPHN is fatal in up to 50% of newborn patients […]
– Leqvio® Becomes Fourth RNAi Therapeutic Approved by U.S. FDA and First and Only for Lowering LDL-C in Atherosclerotic Cardiovascular Disease (ASCVD) Which Can Affect Up to 30 Million Americans – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and […]
Publication in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions Found TRIA Aortic Heart Valve Provided Sustained Improvement in Heart Valve Function to One-Year with Good Safety Profile SALT LAKE CITY–(BUSINESS WIRE)–Foldax®, Inc. today announced publication of the first clinical results for its TRIA™ biopolymer heart valve – […]
The revolutionary Harmony Transcatheter Pulmonary Valve is placed via cardiac catheterization and provides an alternative to open-heart surgery for patients with leaky pulmonary valves. TAMPA, Fla., Dec. 20, 2021 /PRNewswire/ — Jasmine Harvey, 21, was born with the complex congenital heart condition tetralogy of Fallot and underwent open-heart surgery at St. Joseph’s Children’s Hospital when she […]
